 Marseille, Jan. 05, 2021 GLOBE NEWSWIRE -- Innate Pharma SA Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA Innate or the Company today announced that Sanofi has made the decision to progress IPH6101SAR443579 into investigational new drug IND-enabling studies. IPH6101SAR443579 is a NKp46-based NK cell engager NKCE using Innates proprietary multispecific antibody format Gauthier et al. Cell 2019 . 